Danish Novo Nordisk’s patent on semaglutide — the active ingredient in weight loss drug Ozempic expires in 2026. In the meantime, Chinese firms have been hard at work, trying to develop at least 15 generic versions of Ozempic and Wegovy. What does that mean for the pharmaceutical market?
In other news, a crisis is brewing at VIP industries as amid declining profits, Nisaba Godrej resigned as an independent director on the board of VIP Industries. What's happening to the legacy suitcase company VIP? Tune in!